Cargando…
Weak Agonistic LPS Restores Intestinal Immune Homeostasis
Generated by gram-negative bacteria, lipopolysaccharides (LPSs) are one of the most abundant and potent immunomodulatory substances present in the intestinal lumen. Interaction of agonistic LPS with the host myeloid-differentiation-2/Toll-like receptor 4 (MD-2/TLR4) receptor complex results in nucle...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838991/ https://www.ncbi.nlm.nih.gov/pubmed/31416777 http://dx.doi.org/10.1016/j.ymthe.2019.07.007 |
_version_ | 1783467316966588416 |
---|---|
author | Steimle, Alex Michaelis, Lena Di Lorenzo, Flaviana Kliem, Thorsten Münzner, Tobias Maerz, Jan Kevin Schäfer, Andrea Lange, Anna Parusel, Raphael Gronbach, Kerstin Fuchs, Kerstin Silipo, Alba Öz, Hasan Halit Pichler, Bernd J. Autenrieth, Ingo B. Molinaro, Antonio Frick, Julia-Stefanie |
author_facet | Steimle, Alex Michaelis, Lena Di Lorenzo, Flaviana Kliem, Thorsten Münzner, Tobias Maerz, Jan Kevin Schäfer, Andrea Lange, Anna Parusel, Raphael Gronbach, Kerstin Fuchs, Kerstin Silipo, Alba Öz, Hasan Halit Pichler, Bernd J. Autenrieth, Ingo B. Molinaro, Antonio Frick, Julia-Stefanie |
author_sort | Steimle, Alex |
collection | PubMed |
description | Generated by gram-negative bacteria, lipopolysaccharides (LPSs) are one of the most abundant and potent immunomodulatory substances present in the intestinal lumen. Interaction of agonistic LPS with the host myeloid-differentiation-2/Toll-like receptor 4 (MD-2/TLR4) receptor complex results in nuclear factor κB (NF-κB) activation, followed by the robust induction of pro-inflammatory immune responses. Here we have isolated LPS from a common gut commensal, Bacteroides vulgatus mpk (BVMPK), which provides only weak agonistic activity. This weak agonistic activity leads to the amelioration of inflammatory immune responses in a mouse model for experimental colitis, and it was in sharp contrast to strong agonists and antagonists. In this context, the administration of BVMPK LPS into mice with severe intestinal inflammation re-established intestinal immune homeostasis within only 2 weeks, resulting in the clearance of all symptoms of inflammation. These inflammation-reducing properties of weak agonistic LPS are grounded in the induction of a special type of endotoxin tolerance via the MD-2/TLR4 receptor complex axis in intestinal lamina propria CD11c(+) cells. Thus, weak agonistic LPS represents a promising agent to treat diseases involving pathological overactivation of the intestinal immune system, e.g., in inflammatory bowel diseases. |
format | Online Article Text |
id | pubmed-6838991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-68389912020-11-06 Weak Agonistic LPS Restores Intestinal Immune Homeostasis Steimle, Alex Michaelis, Lena Di Lorenzo, Flaviana Kliem, Thorsten Münzner, Tobias Maerz, Jan Kevin Schäfer, Andrea Lange, Anna Parusel, Raphael Gronbach, Kerstin Fuchs, Kerstin Silipo, Alba Öz, Hasan Halit Pichler, Bernd J. Autenrieth, Ingo B. Molinaro, Antonio Frick, Julia-Stefanie Mol Ther Original Article Generated by gram-negative bacteria, lipopolysaccharides (LPSs) are one of the most abundant and potent immunomodulatory substances present in the intestinal lumen. Interaction of agonistic LPS with the host myeloid-differentiation-2/Toll-like receptor 4 (MD-2/TLR4) receptor complex results in nuclear factor κB (NF-κB) activation, followed by the robust induction of pro-inflammatory immune responses. Here we have isolated LPS from a common gut commensal, Bacteroides vulgatus mpk (BVMPK), which provides only weak agonistic activity. This weak agonistic activity leads to the amelioration of inflammatory immune responses in a mouse model for experimental colitis, and it was in sharp contrast to strong agonists and antagonists. In this context, the administration of BVMPK LPS into mice with severe intestinal inflammation re-established intestinal immune homeostasis within only 2 weeks, resulting in the clearance of all symptoms of inflammation. These inflammation-reducing properties of weak agonistic LPS are grounded in the induction of a special type of endotoxin tolerance via the MD-2/TLR4 receptor complex axis in intestinal lamina propria CD11c(+) cells. Thus, weak agonistic LPS represents a promising agent to treat diseases involving pathological overactivation of the intestinal immune system, e.g., in inflammatory bowel diseases. American Society of Gene & Cell Therapy 2019-11-06 2019-07-19 /pmc/articles/PMC6838991/ /pubmed/31416777 http://dx.doi.org/10.1016/j.ymthe.2019.07.007 Text en © 2019 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Steimle, Alex Michaelis, Lena Di Lorenzo, Flaviana Kliem, Thorsten Münzner, Tobias Maerz, Jan Kevin Schäfer, Andrea Lange, Anna Parusel, Raphael Gronbach, Kerstin Fuchs, Kerstin Silipo, Alba Öz, Hasan Halit Pichler, Bernd J. Autenrieth, Ingo B. Molinaro, Antonio Frick, Julia-Stefanie Weak Agonistic LPS Restores Intestinal Immune Homeostasis |
title | Weak Agonistic LPS Restores Intestinal Immune Homeostasis |
title_full | Weak Agonistic LPS Restores Intestinal Immune Homeostasis |
title_fullStr | Weak Agonistic LPS Restores Intestinal Immune Homeostasis |
title_full_unstemmed | Weak Agonistic LPS Restores Intestinal Immune Homeostasis |
title_short | Weak Agonistic LPS Restores Intestinal Immune Homeostasis |
title_sort | weak agonistic lps restores intestinal immune homeostasis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838991/ https://www.ncbi.nlm.nih.gov/pubmed/31416777 http://dx.doi.org/10.1016/j.ymthe.2019.07.007 |
work_keys_str_mv | AT steimlealex weakagonisticlpsrestoresintestinalimmunehomeostasis AT michaelislena weakagonisticlpsrestoresintestinalimmunehomeostasis AT dilorenzoflaviana weakagonisticlpsrestoresintestinalimmunehomeostasis AT kliemthorsten weakagonisticlpsrestoresintestinalimmunehomeostasis AT munznertobias weakagonisticlpsrestoresintestinalimmunehomeostasis AT maerzjankevin weakagonisticlpsrestoresintestinalimmunehomeostasis AT schaferandrea weakagonisticlpsrestoresintestinalimmunehomeostasis AT langeanna weakagonisticlpsrestoresintestinalimmunehomeostasis AT paruselraphael weakagonisticlpsrestoresintestinalimmunehomeostasis AT gronbachkerstin weakagonisticlpsrestoresintestinalimmunehomeostasis AT fuchskerstin weakagonisticlpsrestoresintestinalimmunehomeostasis AT silipoalba weakagonisticlpsrestoresintestinalimmunehomeostasis AT ozhasanhalit weakagonisticlpsrestoresintestinalimmunehomeostasis AT pichlerberndj weakagonisticlpsrestoresintestinalimmunehomeostasis AT autenriethingob weakagonisticlpsrestoresintestinalimmunehomeostasis AT molinaroantonio weakagonisticlpsrestoresintestinalimmunehomeostasis AT frickjuliastefanie weakagonisticlpsrestoresintestinalimmunehomeostasis |